Clinicians Should Consider Patient Concerns Amid Rise in Early-Onset Cancers

Commentary
Video

Clinicians should not dismiss the concerns of younger patients who suspect they may have breast cancer, especially amid an increase in early-onset disease according to Monique Gary, DO, MSc, FACS.

Although breast cancer has been historically recognized as a disease associated with aging, it is crucial to encourage younger populations of patients to stay vigilant of potential symptoms due to earl-onset incidence increasing over time, Monique Gary, DO, MSc, FACS, said during a conversation with CancerNetwork®.

In an interview concerning the findings from a study published in JAMA Network Open that highlighted a rise in early-onset breast cancer from 2010 to 2019, Gary, a breast surgeon and medical director at Grand View Health, emphasized the importance of listening to patient concerns and taking them seriously, as it could be a matter of life or death.

Transcript:

We should pay attention to the patient, and not just the patterns. Too often, young people are dismissed because they don’t fit the typical mold of what cancer looks like. We have historically been taught that cancer is largely a disease of aging. And while there are juvenile and pediatric cancers, historically, breast cancer hasn’t been one of them, [as well as] uterine cancer and colon cancer. Because we’re seeing younger and younger people develop these cancers, it means that we need to pay attention to those symptoms, [and] it means that we need to teach young people to pay attention to their bodies and not just power through without understanding the changes because they’re too young for screening. It’s not like you just have to wait for a colonoscopy. By the time you wait for that colonoscopy, you may have advanced disease or you could be dead.

You have to learn to listen to your body. We have to teach that we have to learn to listen to and believe our patients. Those are really great takeaways from this.

Reference

Koh B, Hao Tan DJ, Ng HN, et al. Patterns in cancer incidence among people younger than 50 years in the US, 2010 to 2019. JAMA Netw Open. 2023;6(8):e2328171. doi:10.1001/jamanetworkopen.2023.28171

Recent Videos
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.